vs
Side-by-side financial comparison of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) and AbCellera Biologics Inc. (ABCL). Click either name above to swap in a different company.
AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $574.1K, roughly 78.1× ASCENTAGE PHARMA GROUP INTERNATIONAL).
Ascentage Pharma Group International is a global clinical-stage biotechnology company specializing in developing novel targeted therapies for cancers, chronic viral infections, and age-related diseases. It focuses on small molecule drugs targeting apoptosis pathways and other key oncogenic mechanisms, with operations spanning China, the U.S., and other global markets, serving patients with unmet medical needs worldwide.
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
AAPG vs ABCL — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $574.1K | $44.9M |
| Net Profit | — | $-8.9M |
| Gross Margin | — | — |
| Operating Margin | — | -63.7% |
| Net Margin | — | -19.9% |
| Revenue YoY | — | 788.4% |
| Net Profit YoY | — | 73.9% |
| EPS (diluted) | — | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $574.1K | $44.9M | ||
| Q3 25 | — | $9.0M | ||
| Q2 25 | $32.6M | $17.1M | ||
| Q1 25 | — | $4.2M | ||
| Q4 24 | — | $5.0M | ||
| Q3 24 | — | $6.5M | ||
| Q2 24 | — | $7.3M | ||
| Q1 24 | — | $10.0M |
| Q4 25 | — | $-8.9M | ||
| Q3 25 | — | $-57.1M | ||
| Q2 25 | $11.4M | $-34.7M | ||
| Q1 25 | — | $-45.6M | ||
| Q4 24 | — | $-34.2M | ||
| Q3 24 | — | $-51.1M | ||
| Q2 24 | — | $-36.9M | ||
| Q1 24 | — | $-40.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 90.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -63.7% | ||
| Q3 25 | — | -851.8% | ||
| Q2 25 | — | -290.2% | ||
| Q1 25 | — | -1479.6% | ||
| Q4 24 | — | -1441.0% | ||
| Q3 24 | — | -1439.4% | ||
| Q2 24 | — | -1276.2% | ||
| Q1 24 | — | -551.5% |
| Q4 25 | — | -19.9% | ||
| Q3 25 | — | -637.8% | ||
| Q2 25 | — | -203.3% | ||
| Q1 25 | — | -1077.2% | ||
| Q4 24 | — | -677.6% | ||
| Q3 24 | — | -785.4% | ||
| Q2 24 | — | -504.3% | ||
| Q1 24 | — | -408.0% |
| Q4 25 | — | $-0.03 | ||
| Q3 25 | — | $-0.19 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $-0.17 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $128.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $966.9M |
| Total Assets | — | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $128.5M | ||
| Q3 25 | — | $83.2M | ||
| Q2 25 | — | $92.4M | ||
| Q1 25 | — | $159.3M | ||
| Q4 24 | — | $156.3M | ||
| Q3 24 | — | $126.6M | ||
| Q2 24 | — | $148.3M | ||
| Q1 24 | — | $123.6M |
| Q4 25 | — | $966.9M | ||
| Q3 25 | — | $964.0M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-34.7M |
| Free Cash FlowOCF − Capex | — | $-44.6M |
| FCF MarginFCF / Revenue | — | -99.4% |
| Capex IntensityCapex / Revenue | — | 21.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-174.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-34.7M | ||
| Q3 25 | — | $-52.6M | ||
| Q2 25 | — | $-32.4M | ||
| Q1 25 | — | $-11.6M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | — | $-28.9M | ||
| Q2 24 | — | $-30.0M | ||
| Q1 24 | — | $-41.7M |
| Q4 25 | — | $-44.6M | ||
| Q3 25 | — | $-61.5M | ||
| Q2 25 | — | $-45.8M | ||
| Q1 25 | — | $-22.2M | ||
| Q4 24 | — | $-23.6M | ||
| Q3 24 | — | $-47.4M | ||
| Q2 24 | — | $-50.1M | ||
| Q1 24 | — | $-65.8M |
| Q4 25 | — | -99.4% | ||
| Q3 25 | — | -687.0% | ||
| Q2 25 | — | -267.9% | ||
| Q1 25 | — | -524.0% | ||
| Q4 24 | — | -468.0% | ||
| Q3 24 | — | -728.4% | ||
| Q2 24 | — | -683.8% | ||
| Q1 24 | — | -661.5% |
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 99.7% | ||
| Q2 25 | — | 78.2% | ||
| Q1 25 | — | 251.1% | ||
| Q4 24 | — | 309.6% | ||
| Q3 24 | — | 284.6% | ||
| Q2 24 | — | 274.6% | ||
| Q1 24 | — | 242.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
